NCT02720094: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 503 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02720094 |
|---|---|
| Title | A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine For Pre-Exposure Prophylaxis in HIV-Uninfected Men and Transgender Women Who Have Sex With Men |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 31, 2016 |
| Completion date | May 14, 2020 |
| Required reporting date | May 14, 2021, midnight |
| Actual reporting date | Sept. 29, 2022 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 503 |